Merck India appoints Pratima Reddy as Country Speaker
Mumbai: Merck, a science and technology company, today announced that Pratima Reddy as their Country Speaker for India. Pratima takes on this role in addition to leading healthcare strategy and operations in India as GM and Managing Director of Merck Specialities India Pvt Ltd. In her current role, Pratima continues to demonstrate focused leadership to drive positive business...
Mumbai: Merck, a science and technology company, today announced that Pratima Reddy as their Country Speaker for India. Pratima takes on this role in addition to leading healthcare strategy and operations in India as GM and Managing Director of Merck Specialities India Pvt Ltd. In her current role, Pratima continues to demonstrate focused leadership to drive positive business outcomes through inclusive and strategic thinking and collaborative execution.
“It is an honour for me represent Merck India as its Country Speaker. I am passionately committed to upholding and further building on the Merck brand and fostering strong industry relations within the country. I look forward to collaborating with leaders across the company’s businesses – life science, healthcare and electronics to communicate our purpose, values, and unique offerings to stakeholders. I firmly believe our people are our most valuable asset and a strong & an empowered team is essential to drive innovation, deliver exceptional products or services and exceed customer expectations,” said Pratima Reddy.
Pratima has over 18 years of experience, including over ten years in the pharmaceutical industry. Since joining Merck in October 2013, Pratima has held several significant leadership positions across multiple functions in local and global teams. Prior to taking over as the General Manager of Healthcare India Operations, Pratima was the Regional Franchise Leader (RFL) of the Cardiovascular, Metabolism and Endocrinology (CM&E) franchise in APAC, where she demonstrated exemplary leadership and delivered successful business outcomes.
Read also: USFDA accepts application for Merck KEYTRUDA plus chemotherapy as treatment for Biliary Tract Cancer
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd